News from the University of Arizona Cancer Center

Our mission is to prevent and to cure cancer.

September 2017
Laurence Hurley, PhD, to Be Honored as the Arizona Bioscience Researcher of the Year at the 2017 AZBio Awards

The Arizona Bioindustry Association will honor Laurence Hurley, PhD, of the University of Arizona College of Pharmacy, as the Arizona Bioscience Researcher of the Year at the 2017 AZBio Awards. Arizona life science and business leaders, as well as guests from across the nation, will recognize Dr. Hurley for his legacy of work that has made a significant clinical impact to improve patients’ lives.

Read Full Article

Justina McEvoy Awarded St. Baldrick’s Scholar for Pediatric Cancer Research

Justina McEvoy, PhD, a research member at the University of Arizona Cancer Center and assistant professor in molecular and cellular biology, has been named a St. Baldrick’s Scholar and awarded a $167,000 career development award for her research on rhabdomyosarcoma, a pediatric cancer that affects the developing skeletal muscle in young children.

Rhabdomyosarcoma makes up about 3 percent of all childhood cancers, with nearly 350 new cases each year. More than half of diagnoses occur in children under the age of 10.

Mechanisms that drive this tumor are poorly understood. Next-generation sequencing studies reveal that a subset of pediatric cancers have very few genetic alterations, suggesting that non-genetic mechanisms contribute to tumor progression. Despite the genetic alterations discovered, therapeutics
targeting these mutations have not improved patient survival over the past 25 years. Since more than 60 percent of patients with metastatic disease do not survive, this creates an urgency to identify new vulnerabilities to exploit for therapeutic development.

"Rhabdomyosarcoma has some of the worst survival statistics among solid tumor sarcomas and our goal is focused on changing this," says Dr. McEvoy.

Her research is focused on the long-term goal of understanding the regulation of differentiation during normal development and in pediatric cancers. To aid in this goal, she has developed a research project aimed at studying the epigenetic regulation of differentiation and cancer programs in rhabdomyosarcoma.

"We identified a novel gene that is essential for tumor cells to survive and grow. This is exciting because little is known about the driving mechanisms for this disease and we believe our data points to a brand-new regulator," says Dr. McEvoy.

The St. Baldrick's Foundation was established in 1999 as a not-for-profit organization with a mission to raise funds in an effort to seek cures for childhood cancers. The career-development award helps promising investigators who are early in their careers establish independent research programs.

Based on preliminary analysis, one possible mechanism is deregulation by a group of long noncoding RNAs (lncRNA). This is exciting because lncRNAs play a role in tumorigenesis in other cancer types, including a subset of pediatric tumors, and presents a unique opportunity to develop novel therapeutic approaches for children with rhabdomyosarcoma. Dr. McEvoy hypothesizes that lncRNA deregulation is essential for rhabdomyosarcoma development and data from this study will shed light on the underlying mechanisms that drive this disease and identify potential new therapies.

These exciting findings potentially present new opportunities for therapeutic approaches that would otherwise be beyond our reach. This will have tremendous impact on patients, especially those with metastatic disease since only 20 to 40 percent will survive using current treatments, which have not improved in the past 25 years.
Breast Team Seeks American College of Surgeons' NAPBC Accreditation

It's a busy time for our multidisciplinary breast team, which is in the midst of a lengthy accreditation process. The National Accreditation Program for Breast Centers (NAPBC) recognizes health-care providers that are dedicated to maintaining high standards of care and ambitious goals for quality improvement. NAPBC accreditation will be a beacon to new patients, and an assurance to our current patients that our team stands head and shoulders above the competition.

Beth High, MSN, breast oncology nurse navigator, tells us NAPBC accreditation will demonstrate our desire to "raise our bar a little higher. We already provide excellent care here. Accreditation will let patients know we have passed stringent testing, that we're not average, that we're well above average. They will know when they walk in the door that it's a top-of-the-line place."

After finding a lump in their breast, a frightened patient might scramble for guidance, and Google is a frequent first stop for information. "Many websites say, look for an academic-based medical center and NAPBC-accredited centers, because then you know you're getting quality care," High tells us. Our status as an NAPCB-accredited breast center will be "another pathway to lead patients to us, to give them peace of mind. This increases our visibility and credibility. It demonstrates our superiority in patient care."

The breast team began their application two years ago, a process that has involved intense data collection as well as minor adjustments to their program in order to meet NAPBC standards. The accreditation process will culminate in mid-November with a site visit, which will include a chart audit and attendance at a tumor board meeting.

The UA Cancer Center is the only NCI-designated cancer center headquartered in the state, and is also accredited by the Commission on Cancer, so NAPBC accreditation will further increase our competitiveness with other breast centers in the region.
NAPBC accreditation comes with many perks. The extra national recognition and publicity will only be a plus for our dedicated physicians, while the enhanced standards and commitment to quality will be a plus for our valued patients.

**UA Hosts SING Conference**

Congratulations to Francine Gachupin, PhD, MPH, for organizing the Summer Internship for INdigenous Peoples in Genomics (SING), from July 9 to 15. SING was developed in 2011 as a short course to train Indigenous students and community members in genomics, computational analyses, bioinformatics and bioethics, and to build capacity for scientific research with Native American/Indigenous communities. The UA-SING had a cancer focus and Andrew Kraft, MD, UA Cancer Center director, and Myra Muramoto, MD, MPH, addressed the group of 54 participants and faculty, from across the U.S., New Zealand, Canada and Mexico.

University of Arizona-SING was fortunate to have a tribal councilman and tribal research review board member attend. The New Zealand partners gifted the UA-SING with a beautiful whakairo during their Thursday night dinner; Dr. Gachupin was honored to be the recipient on behalf of UA-SING. SING 2018 will be held at the University of Washington, Seattle, Dr. Gachupin's alma mater.
Banner - UMC Tucson Among U.S. News 'Best Hospitals'; 48th in Cancer

Banner - University Medical Center Tucson has been ranked among the best hospitals in the nation for cancer, geriatrics, gynecology and pulmonary care in U.S. News World Report's 2017-18 "Best Hospitals" ratings, and as "high performing" in four other medical specialties.

The publication also rated Banner - University Medical Center Tucson as the best hospital in Southeastern Arizona and the No. 2 hospital in Arizona, tied with Banner - University Medical Center Phoenix, its sister hospital.

The annual U.S. News Best Hospitals rankings, now in its 28th year, is designed to help patients make informed decisions about where to receive care for life-threatening conditions or for common elective procedures.

"These top rankings are a credit to the caregivers, educators and researchers at Banner - University Medical Center Tucson, who are totally focused on producing outstanding outcomes for our patients," says hospital CEO Tom Dickson.

The Tucson academic medical center was ranked 38th in the medical specialty of gynecology, 42nd in pulmonology, 46th in geriatrics and 48th in cancer out of approximately 4,500 hospitals surveyed across the nation.

Read Full Article
Important Information Regarding Campus IT Updates

The University of Arizona is in the process of several major IT updates that are going to affect you. These include:

1. A new 2-factor authentication process called NetID+ that will replace the old username and password log-in. NetID+ augments security, but you still need to know your username and password. This will be required in order to access email, UAccess and all other UA systems.

2. Microsoft Office 365: In short, all Microsoft computing applications, including email, will be upgraded to a cloud-based platform. This will require a migration process that will be scheduled to take place over a 12-hour period between standard business operating hours.

What this means for you: Campus UITS is scheduled to migrate all UACC employee email on September 16, 2017. Once the migration has taken place, you will need to update your email settings on your computer and mobile email applications. NOTE: You will still be able to use the Outlook application on your desktop, but you will need to upgrade to Office 2016 on PCs.

The UACC IT department is working hard to ensure that there is minimal disruption of services and access to support. In order to effectively navigate the UACC through these changes, UACC IT needs your help to prepare.

Prior to September 16, 2017 (within the next 3 weeks) please:

1. **Sign up for NetID+**
2. **Register with your new Microsoft Office 365 account**

These are separate items, but both will be required in order to have access to your email once it has been migrated to the new platform.

Michael Lukach and Jason Purdy will be available to assist you throughout this process. Please carefully read through the following instructions from UITS:
UITs recommends members of the campus community prepare for migration now, to experience minimal disruption when their individual mailbox migrates. Julie Suess, project manager for the UAConnect365 project, says, "We want to make sure that everyone is ready, so we created a checklist." She encourages everyone migrating to check off the following three actions:

- I have **logged in** to Office 365 to test whether I will be able to reach my email after migration: portal.office.com
  - Requires a NetID password that was created on or after March 6, 2017: netid.arizona.edu
  - Requires NetID+ two-factor authentication enabled: webauth.arizona.edu/netid-plus
  - Instructions at it.arizona.edu/documentation/how-log-office-365
  - The Outlook and Calendar tiles inside Office 365 will give you a redirect link to OWA until your mailbox migrates.
  - If you encounter difficulties, work with your departmental IT staff or the 24/7 IT Support Center now to resolve.
  - Use email.arizona.edu to find your email online before and after migration.

- I have **bookmarked** the following pages:
  - UAConnect365 website, for Before and After Migration Instructions and FAQs: it.arizona.edu/uaconnect365
  - UAConnect 365 App Password, needed to set up email software other than Outlook 2016 (such as Apple Mail, Thunderbird), and mobile apps other than Outlook app (such as iOS Mail, Android Mail): app-pw.catnet.arizona.edu

- I have contact information for my departmental IT support staff, or the 24/7 IT Support Center: 520-626-TECH (8324)

Teresa Banks, from the university's Information Security Office, adds, "Many people ask about using NetID+ when they are traveling, and with NetID+ added to Office 365 we expect even more demand. We recommend they have multiple ways to authenticate your NetID+. There is even an option for printing out a list of codes you can use." She recommended viewing ISO's **Security Guidelines for International Travel** for tips on accessing University services online while traveling, including using NetID+.

More Information: **UAConnect365 Migration Project**
Tech Launch Arizona, the technology commercialization office of the University of Arizona, reports across-the-board increases in startup companies, licenses agreements for UA technology, invention disclosures and patent filings for fiscal 2017 (July 1, 2016 to June 30, 2017). Tech Parks Arizona also grew over the same period, with new client agreements with companies from Israel, Mexico and the U.S. and increased occupancy rates for a total of 44 companies that employ more than 5,990 people -- a 9.9 percent increase over the previous year.

Of the 15 startups formed in fiscal 2017, two are built around inventions developed by UA Cancer Center researchers:

- Catalina Pharma Inc., developing a TRPV1-inhibitor as treatment for anesthesia-induced hypothermia, invented by Amol Patwardhan, MD, PhD, assistant professor in the Department of Anesthesiology and Pharmacology in the UA College of Medicine - Tucson, and Frank Porreca, PhD, associate department head of pharmacology in the UA Cancer Center.
- Nanosonic Bioreagents, manufacturing reagents with applications in sample preparation for high-throughput DNA sequencing, medical imaging, and clinical therapy in conjunction with chemotherapy and ablation therapy, co-invented by Terry Matsunaga, PharmD, PhD, of the UA Cancer Center and the College of Medicine - Tucson.

Read Full Article

Shared Resources

SHARED RESOURCE HIGHLIGHT: Analytical Chemistry
Specifically, the ACSR has the following aims:

- To provide Cancer Center investigators with support in the development of chromatography-based analytical methods;
- To provide Cancer Center investigators with support in routine quantitative analysis of clinical and preclinical samples;
- To provide consultation in pharmacokinetic trial design and pharmacokinetic and pharmacodynamic data analysis.

By continuing to provide state-of-the-art analytical and pharmacokinetic services, the ACSR laboratory should greatly augment preclinical drug discovery efforts and stimulate the incorporation of pharmacokinetic endpoints in clinical trials.

**Services**

- Consultation on study design including selection of existing assays and/or development of new assays
- Development and implementation of analytical chemistry methods for quantification of cancer therapeutic and preventive agents, nutrients, carcinogens, and endogenous biochemicals in biospecimens
- Quantitative analysis of cancer therapeutic and preventive agents, nutrients, carcinogens, and endogenous biochemicals in clinical and preclinical specimens
- Pharmacokinetic study design and pharmacokinetic and pharmacodynamic data analysis
• Targeted metabolomic analysis and untargeted metabolomic profiling

Services provided by the ACSR are essential for the assessment of drug/nutrient/carcinogen exposure and disposition, and for the measurement of endogenous biochemicals as surrogate cancer-risk biomarkers and endpoint biomarkers in intervention studies. These measurements are indispensable in many established lines of research in the UACC, including preclinical and clinical evaluation of cancer therapeutic drugs and preventive interventions, assessment of biological, environmental, and lifestyle factors associated with cancer risk and disease progression, and identification of potential targets for intervention.

**Equipment/Instruments**
State-of-the-art equipment and sophisticated analytical chemistry techniques are provided by the ACSR to cover a broad variety of needs. Personnel are trained experts in the operation and maintenance of this equipment. They have the expertise to develop and optimize the appropriate methods. Available equipment includes:

- Liquid Chromatography-Mass Spectrometry (LC-MS)
- Gas Chromatography-Mass Spectrometry (GC-MS)
- Atomic Absorption Spectrophotometry (AAS)
- High Performance Liquid Chromatography (HPLC)
- Ultra Performance Liquid Chromatography - Quadrupole/Time of Flight Mass Spectrometry (UPLC-QTOF)

Read more about the Analytical Chemistry Shared Resource here.

**Shared Resources to Enhance Research Efforts**
The University of Arizona Cancer Center supports eight Shared Resources funded by the Cancer Center Support Grant and two other resources funded by other sources, intended to provide access to technology that enhances the research productivity of the Cancer Center and provides a basis for scientific interaction and consultation, as well as access to services that facilitate the research and strengthen the administrative and organizational cohesion of the center.

The University of Arizona Cancer Center Shared Resources:
National Conversation


Science Magazine: "Zebrafish implanted with a cancer patient's tumor could guide cancer treatment":

Healthline: "Alternative Treatments More Than Double Risk of Death for Cancer Patients":

CBS News: "Could high doses of vitamin B supplements raise lung cancer risk?"
New York Times: "More Young People Are Dying of Colon Cancer"

Call for Collaborations

Share Your Stories and Ideas

Please send news items, announcements, calls for collaboration, upcoming events, comments, and anything else that you can think of to Cody Cassidy, ccassidy@uacc.arizona.edu.
NCI Funding Opportunities

If you are interested in pursuing any of these funding opportunities, please contact Cindy Cowen at cowenc@email.arizona.edu.

Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (UG3/UH3) (RFA-TR-17-002)
Application due date: September 15, 2017

(R21) Innovative Technologies for Cancer-Relevant Biospecimen Science (RFA-CA-17-012)
Application due dates: September 26, 2017

(R01) Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (PAR-16-276)
Application due dates: October 13, 2017; June 13, 2018; October 15, 2018; June 13, 2019

(R21) Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (PAR-16-277)
Application due dates: October 13, 2017; June 13, 2018; October 15, 2018; June 13, 2019

Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R01) (PAR-16-276)
Application due dates: October 13, 2017; June 13, 2018; October 15, 2018; June 13, 2019; LOI 30 days before due date

Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R21) (PAR-16-277)
Application due dates: October 13, 2017; June 13, 2018; October 15, 2018; June 13, 2019; LOI 30 days before due date
Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24) (PAR-16-385)
Application due date(s): November 17, 2017; June 14, 2018

**PHS 2017-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) (PA-17-302)
Application due date: September 5, 2017; January 5, 2018, April 5, 2018

**PHS 2017-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]) (PA-17-303)
Application due date: September 5, 2017; January 5, 2018, April 5, 2018

(U01) Biological Comparison in Patient-Derived Models of Cancer (PAR-16-344)
Application due dates: September 6, 2017; March 7, 2018; September 6, 2018; March 6, 2019

Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (UG3/UH3) (RFA-TR-17-002)
Application due date: September 15, 2017

Tobacco Regulatory Science (R21) (RFA-OD-17-014)
Application due date: September 18, 2017, February 13, 2018, July 17, 2018, February 13, 2019

Tobacco Regulatory Science Small Grant Program for New Investigators (R03) (RFA-OD-17-012)
Application due date: September 18, 2017, February 13, 2018, July 17, 2018, February 13, 2019

(P01) National Cancer Institute Program Project Applications (PAR-16-457)
Application due date (standard): September 25, 2017

Limited Competition: Lasker Clinical Research Scholars Transition Award (R00) (PAR-17-450)
Application due date: September 25, 2017; January 7, 2018; January 25, 2018; May 7, 2018; May 25, 2018; September 7, 2018
(R21) Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research 
(RFA-CA-17-010)  
Application due dates: September 26, 2017

(R33) Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research 
(RFA-CA-17-011)  
Application due dates: September 26, 2017

(R21) Innovative Technologies for Cancer-Relevant Biospecimen Science 
(RFA-CA-17-012)  
Application due dates: September 26, 2017

Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems (R01)  
Synopsis 1 
(PAR-17-093)  
Application due date: October 3, 2019

Leveraging Population-based Cancer Registry Data to Study Health Disparities (R01)  
(PA-17-289)  
National Cancer Institute  
Application due date: October 5, 2017; February 5, 2018; June 5, 2017

Reducing Health Disparities among Minority and Underserved Children (R01)  
(PAR-17-118)  
Application due date: October 5, 2017

The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R01)  
(PA-17-440)  
Application due date: October 5, 2017; February 5, 2018; June 5, 2018

Assay development and screening for discovery of chemical probes or therapeutic agents (R01)  
(PAR-17-438)  
Application due date: October 5, 2017; February 5, 2018; June 5, 2018

Synthetic Biology for Engineering Applications (R01)  
(PAR-17-334)  
Application due date: October 5, 2017; February 5, 2018; June 5, 2018

Using Small Molecules and Molecular Genetics to Identify Novel Targets and Mechanisms Contributing to Tumor Immune Evasion (R01)  
(PA-17-330)  
Application due date: October 5, 2017; February 5, 2018; June 5, 2018
Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01) (PAR-16-380)
Application due date(s): October 10, 2017; April 11, 2018; October 10, 2018; April 11, 2019, October 11, 2019

U.S. Tobacco Control Policies to Reduce Health Disparities (R01) (PAR-17-217)
Application due date: October 11, 2017; June 13, 2018; October 11, 2018; June 13, 2019; October 11, 2019; June 15, 2020

U.S. Tobacco Control Policies to Reduce Health Disparities (R21) (PAR-17-218)
Application due date: October 11, 2017; June 13, 2018; October 11, 2018; June 13, 2019; October 11, 2019; June 15, 2020

Expanding Genome Integrity Assays to Population Studies (U01) (RFA-ES-17-006)
Application due date: October 13, 2017

**Administrative Supplements for Research on Dietary Supplements (Admin Supp) (PA-17-307)
Application due date: October 15, 2017; January 15, 2018; or April 15, 2018

Leveraging Population-based Cancer Registry Data to Study Health Disparities (R21) (PA-17-288)
Application due date: October 16, 2017; February 16, 2018; June 16, 2018

The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R21) (PA-17-449)
Application due date: October 16, 2017; February 16, 2018; June 16, 2018

Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R21) (PA-17-446)
Application due date: October 16, 2017; February 16, 2018; June 16, 2018

NIBIB Exploratory/Developmental Research Grant Program (R21) (PAR-17-441)
Application due date: October 16, 2017; February 16, 2018; June 16, 2018

Consortium on Translational Research in Early Detection of Liver Cancer (Clinical and Research Centers (U01) (RFA-CA-17-025)
Coordinating Center for the Consortium of Translational Research in Early Detection of Liver Cancer (U24)  
(RFA-CA-17-028)  
Application due date: October 24, 2017 by 5 p.m. local time of applicant organization

Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment (U01)  
(RFA-CA-17-029)  
Application due date: October 24, 2017; January 23, 2018

Limited Competition: A Data Resource for Analyzing Blood and Marrow Transplants (U24)  
(RFA-CA-17-031)  
Application due date: October 26, 2017

Metabolomics Core for the Undiagnosed Diseases Network (UDN) Phase II (U01) (RFA-RM-17-015)  
Application due date: November 2, 2017

Collaborative Research Network for Fusion Oncoproteins in Childhood Cancers (U54)  
(RFA-CA-17-049)  
Application due date: November 15, 2017

Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24)  
(PAR-16-385)  
Application due date(s): November 17, 2017; June 14, 2018

(PAR-17-472)  
Application due date: November 27, 2017 by 5 p.m. local time of applicant organization

**Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01)  
(PAR-17-473)  
Application due date: November 27, 2017 by 5 p.m. local time of applicant organization

**Notice of NCI’s participation on PA-17-462 "Symptoms Cluster Characterization in Chronic Conditions (R01)"  
(NOT-CA-17-083)
Application due date: January 5, 2018

**Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01) (RFA-CA-17-041)**
Application due date: January 9, 2018 by 5 p.m. local time of applicant organization

**Notice of Correction to Activity Code in PA-17-460 "Biology of Lung, and Head and Neck Preneoplasias (R21 - Clinical Trial Not Allowed)" (NOT-CA-17-078)**
Application due date: January 16, 2018

**Notice of NCI's participation on PA-17-461 "Symptoms Cluster Characterization in Chronic Conditions (R21)" (NOT-CA-17-082)**
Application due date: January 16, 2018

Population Assessment of Tobacco and Health (PATH) Biospecimen Access (X01) (PAR-17-458)
Application due date: January 31, 2018, July 31, 2018, January 31, 2019, July 31, 2019

Symptom Cluster Characterization in Chronic Conditions (R01) (PA-17-462)
Application due date: February 5, 2018; June 5, 2018; October 5, 2018

Ethical, Legal, and Social Implications (ELSI) of Genomics Research Project Grant Program (R01) (PA-17-325)
Application due date: February 5, 2018; June 8, 2018; October 5, 2018

Tobacco Regulatory Science Small Grant Program for New Investigators (R03) (RFA-OD-17-008)
Application due dates: February 13, 2018, July 17, 2018; February 13, 2019

Tobacco Regulatory Science (R01) (RFA-OD-17-007)
Application due dates: February 13, 2018, July 17, 2018; February 13, 2019

Symptom Cluster Characterization in Chronic Conditions (R21) (PA-17-461)
Application due date: February 16, 2018; June 16, 2018; October 16, 2018

Biology of Lung, and Head and Neck Preneoplasias (R21) (PA-17-460)
Application due date: February 16, 2018; June 16, 2018; October 16, 2018
Biology of Lung, and Head and Neck Preneoplasias (R01) (PA-17-459)
Application due date: February 5, 2018; June 5, 2018; October 5, 2018

Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R21) (PA-17-323)
Application due date: March 16, 2018; July 16, 2018; November 16, 2018

Ethical, Legal, and Social Implications (ELSI) of Genomics Small Research Grant Program (R03) (PA-17-324)
Application due date: March 16, 2018; 2018; July 16, 2018; November 16, 2018

Centers of Excellence in Genomic Science (CEGS) (RM1) (PAR-16-436)
National Human Genome Research Institute
Application Receipt/Submission Date(s): May 21, 2018; May 20, 2019, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

NCI Mentored Patient-Oriented Research Career Development Award to Promote Diversity (K23) (PAR-16-399)
No LOI required
Application due date(s): Standard

NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08) (PAR-16-400)
No LOI required
Application due date(s): Standard

NCI Mentored Research Scientist Development Award to Promote Diversity (K01) (PAR-16-401)
No LOI required
Application due date(s): Standard

Gateway for Cancer Research
https://www.gatewaycr.org/research/apply-for-a-grant/
Applications accepted on rolling basis

Pancreatic Cancer Action Network - NCI, Frederick National Laboratory for Cancer Research KRAS Travel Scholarship
2017 research funding opportunities
Application due date: rolling

If you are interested in pursuing any of these funding opportunities, please contact Cindy Cowen at cowenc@email.arizona.edu.

Visit the UACC Website

The University of Arizona Cancer Center
1515 N. Campbell Ave.
Tucson, AZ 85724